Title: Management of type 1 gastric neuroendocrine tumors: An 11-year retrospective single-
center study
Version: 2 Date: 04 Aug 2023
Reviewer's report:
The paper provides valuable information on the clinicopathological characteristics, treatment
outcomes, and prognosis of type 1 gastric neuroendocrine tumors (NETs).
The large sample size and long follow-up period in a single-center study are commendable,
especially considering the rarity of these tumors.
The use of standardized diagnostic criteria and classification and the inclusion of treatment
interventions and the analysis of risk factors for recurrence help in understanding the disease
management.
Weaknesses that could be improved:
• The introduction is well-written, but it could benefit from a stronger rationale for why the
study is important. For example, discussing the increasing incidence of type 1 gastric NETs and
the challenges in accurate classification and management would add context (see also PMID:
35807078 and PMID: 37497604).
• The discussion of results in the paper is minimal. The authors should interpret the findings,
compare them with existing literature, and discuss the implications for clinical practice (see
PMID: 37497604, PMID: 37401795).
• The statistical analyses could be more robust. The authors could use more advanced statistical
methods, such as multivariate regression, to explore potential confounding factors affecting
recurrence risk.
• The study is retrospective, which may introduce biases and limit the ability to draw
causal conclusions. The authors should acknowledge this limitation and suggest the need for
prospective studies to validate the findings.
• The language and grammar need improvement in several sections. A thorough proofreading
and editing are necessary to enhance the overall clarity of the paper.
• The role of proton pump inhibitors (PPIs) in type 1 gastric neuroendocrine tumors (NETs) has
not been evaluated in this study. Even if the Authors didn’t present their data, the absence of PPI
evaluation in this study should be acknowledged and discussed in the context of potential clinical
implications, as a potential risk factor of occurrence or recurrence (see PMID: 26059834).
Title: Management of type 1 gastric neuroendocrine tumors: An 11-year retrospective single-
center study
Version: 2 Date: 04 Aug 2023
Reviewer's report:
The paper provides valuable information on the clinicopathological characteristics, treatment
outcomes, and prognosis of type 1 gastric neuroendocrine tumors (NETs).
The large sample size and long follow-up period in a single-center study are commendable,
especially considering the rarity of these tumors.
The use of standardized diagnostic criteria and classification and the inclusion of treatment
interventions and the analysis of risk factors for recurrence help in understanding the disease
management.
Weaknesses that could be improved:
• The introduction is well-written, but it could benefit from a stronger rationale for why the
study is important. For example, discussing the increasing incidence of type 1 gastric NETs and
the challenges in accurate classification and management would add context (see also PMID:
35807078 and PMID: 37497604).
• The discussion of results in the paper is minimal. The authors should interpret the findings,
compare them with existing literature, and discuss the implications for clinical practice (see
PMID: 37497604, PMID: 37401795).
• The statistical analyses could be more robust. The authors could use more advanced statistical
methods, such as multivariate regression, to explore potential confounding factors affecting
recurrence risk.
• The study is retrospective, which may introduce biases and limit the ability to draw
causal conclusions. The authors should acknowledge this limitation and suggest the need for
prospective studies to validate the findings.
• The language and grammar need improvement in several sections. A thorough proofreading
and editing are necessary to enhance the overall clarity of the paper.
• The role of proton pump inhibitors (PPIs) in type 1 gastric neuroendocrine tumors (NETs) has
not been evaluated in this study. Even if the Authors didn’t present their data, the absence of PPI
evaluation in this study should be acknowledged and discussed in the context of potential clinical
implications, as a potential risk factor of occurrence or recurrence (see PMID: 26059834).
Please review this paper.
user
Title: Management of type 1 gastric neuroendocrine tumors: An 11-year retrospective single-
center study
Version: 2 Date: 04 Aug 2023
Reviewer's report:
The paper provides valuable information on the clinicopathological characteristics, treatment
outcomes, and prognosis of type 1 gastric neuroendocrine tumors (NETs).
The large sample size and long follow-up period in a single-center study are commendable,
especially considering the rarity of these tumors.
The use of standardized diagnostic criteria and classification and the inclusion of treatment
interventions and the analysis of risk factors for recurrence help in understanding the disease
management.
Weaknesses that could be improved:
• The introduction is well-written, but it could benefit from a stronger rationale for why the
study is important. For example, discussing the increasing incidence of type 1 gastric NETs and
the challenges in accurate classification and management would add context (see also PMID:
35807078 and PMID: 37497604).
• The discussion of results in the paper is minimal. The authors should interpret the findings,
compare them with existing literature, and discuss the implications for clinical practice (see
PMID: 37497604, PMID: 37401795).
• The statistical analyses could be more robust. The authors could use more advanced statistical
methods, such as multivariate regression, to explore potential confounding factors affecting
recurrence risk.
• The study is retrospective, which may introduce biases and limit the ability to draw
causal conclusions. The authors should acknowledge this limitation and suggest the need for
prospective studies to validate the findings.
• The language and grammar need improvement in several sections. A thorough proofreading
and editing are necessary to enhance the overall clarity of the paper.
• The role of proton pump inhibitors (PPIs) in type 1 gastric neuroendocrine tumors (NETs) has
not been evaluated in this study. Even if the Authors didn’t present their data, the absence of PPI
evaluation in this study should be acknowledged and discussed in the context of potential clinical
implications, as a potential risk factor of occurrence or recurrence (see PMID: 26059834).
assistant